We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Ultrasensitive Test Detects and Serially Monitors Intact Virus Levels in COVID-19 Patients

By LabMedica International staff writers
Posted on 24 Jan 2025
Print article
Image: Clinical workflow and viral detection using the virusHB-Chip (Photo courtesy of Science Advances, DOI:10.1126/sciadv.adh1167)
Image: Clinical workflow and viral detection using the virusHB-Chip (Photo courtesy of Science Advances, DOI:10.1126/sciadv.adh1167)

The ability to isolate and detect whole viruses from complex biofluids could enhance our understanding of how severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), as well as other viral infections, spreads within the host, providing valuable insights into their dynamics. Quantifying whole viral particles could inform infectivity and reveal a potential link between viral load and organ damage. Researchers have now found that a method originally created for cancer detection can also identify and track even trace amounts of intact SARS-CoV-2 viral particles in blood and other fluids from patients with acute COVID-19 infections, offering promise for improving future treatment strategies.

In the early days of the pandemic, scientists at Mass General Brigham (Somerville, MA, USA) sought to adapt their cancer vesicle isolation technique to detect SARS-CoV-2 in biofluids like blood, stool, and saliva. They quickly assembled a multidisciplinary team to adapt their technology and expand the potential for detecting intact viruses. Their research, published in Science Advances, demonstrated that this method could detect as few as three viral particles in 1 milliliter of blood. When applied to more than 150 samples (103 plasma, 36 saliva, and 29 stool samples) from COVID-19 patients, the technique accurately measured viral levels over time, with intact viral particles detectable up to 50 days after the initial infection.

“With clinical needs changing, the ability to serially monitor viral load in this manner has great potential for guiding the treatment of patients with long Covid,” said co–senior author Shannon L. Stott, PhD. “This versatile technology could also have widespread applications in viral monitoring for current and future infectious diseases.”

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
New
Multi-Channel Pipettor
BioPette Plus
New
Enterovirus Infection Test
Virotech Enterovirus IgM ELISA Kit

Print article

Channels

Immunology

view channel

3D Bioprinted Gastric Cancer Model Uses Patient-Derived Tissue Fragments to Predict Drug Response

Tumor heterogeneity presents a major obstacle in the development and treatment of cancer therapies, as patients' responses to the same drug can differ, and the timing of treatment significantly influences prognosis. Consequently, technologies that predict the effectiveness of anticancer treatments are essential in minimizing... Read more

Pathology

view channel
Image: The OmicsFootPrint AI tool could open doors to new discoveries (Photo courtesy of Mayo Clinic)

Revolutionary AI Tool Transforms Disease Visualization

Genes serve as the body's blueprint, while proteins execute the instructions within those blueprints to maintain cell function. Occasionally, alterations in these instructions—known as mutations—can interfere... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.